Associated Banc Corp purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 177,588 shares of the medical research company's stock, valued at approximately $47,745,000. IQVIA accounts for 1.1% of Associated Banc Corp's holdings, making the stock its 18th biggest position. Associated Banc Corp owned about 0.11% of IQVIA at the end of the most recent quarter.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in IQVIA during the 2nd quarter valued at $2,811,292,000. Dimensional Fund Advisors LP lifted its stake in shares of IQVIA by 4.2% in the first quarter. Dimensional Fund Advisors LP now owns 1,657,696 shares of the medical research company's stock valued at $282,657,000 after buying an additional 66,643 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of IQVIA by 9.0% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,634,264 shares of the medical research company's stock valued at $315,772,000 after buying an additional 134,997 shares in the last quarter. Canada Pension Plan Investment Board acquired a new position in shares of IQVIA during the second quarter valued at about $240,911,000. Finally, Sumitomo Mitsui Trust Group Inc. grew its holdings in shares of IQVIA by 8.3% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,225,851 shares of the medical research company's stock valued at $209,057,000 after buying an additional 93,779 shares during the last quarter. Institutional investors own 89.62% of the company's stock.
Insider Buying and Selling at IQVIA
In related news, insider James G. Berkshire sold 2,668 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total transaction of $697,228.44. Following the completion of the transaction, the insider owned 10,890 shares in the company, valued at approximately $2,845,883.70. This represents a 19.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 1.70% of the company's stock.
IQVIA Trading Up 1.5%
Shares of IQV stock opened at $262.32 on Wednesday. IQVIA Holdings Inc. has a 52-week low of $154.50 and a 52-week high of $284.50. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.83 and a current ratio of 0.83. The company has a 50-day simple moving average of $266.22 and a two-hundred day simple moving average of $210.59. The company has a market capitalization of $43.23 billion, a price-to-earnings ratio of 22.32, a PEG ratio of 2.30 and a beta of 1.16.
IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Tuesday, October 27th. The medical research company reported $3.34 EPS for the quarter, topping the consensus estimate of $3.26 by $0.08. IQVIA had a net margin of 8.05% and a return on equity of 30.02%. The firm had revenue of $4.43 billion for the quarter, compared to analysts' expectations of $4.37 billion. During the same quarter last year, the firm earned $3.00 EPS. The company's quarterly revenue was up 8.0% compared to the same quarter last year. Research analysts anticipate that IQVIA Holdings Inc. will post 11.53 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several equities research analysts have recently commented on the stock. Mizuho boosted their target price on shares of IQVIA from $275.00 to $300.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 7th. Wall Street Zen upgraded IQVIA from a "hold" rating to a "buy" rating in a research note on Saturday, September 12th. Stifel Nicolaus boosted their price objective on IQVIA from $276.00 to $303.00 and gave the stock a "buy" rating in a report on Wednesday, October 14th. UBS Group assumed coverage on IQVIA in a research note on Wednesday, September 30th. They issued a "buy" rating and a $345.00 price objective for the company. Finally, HSBC raised their target price on IQVIA from $280.00 to $300.00 and gave the company a "buy" rating in a report on Tuesday, September 1st. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, IQVIA presently has a consensus rating of "Moderate Buy" and an average price target of $294.21.
View Our Latest Stock Report on IQVIA
IQVIA Company Profile
(
Free Report)
IQVIA Holdings Inc is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop, commercialize and improve products by combining healthcare data with advanced analytics, consulting and technology-enabled services.
Its offerings include clinical research and trial management, real-world evidence, healthcare data and analytics, regulatory and safety services, technology platforms, and commercial solutions.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.